NovoCure Statistics
Total Valuation
NovoCure has a market cap or net worth of $1.99 billion. The enterprise value is $1.80 billion.
Important Dates
The next estimated earnings date is Thursday, May 1, 2025, before market open.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NovoCure has 109.92 million shares outstanding. The number of shares has increased by 1.36% in one year.
| Current Share Class | 109.92M |
| Shares Outstanding | 109.92M |
| Shares Change (YoY) | +1.36% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 9.00% |
| Owned by Institutions (%) | 83.70% |
| Float | 100.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.36 |
| Forward PS | 3.34 |
| PB Ratio | 5.68 |
| P/TBV Ratio | 5.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.46, with a Debt / Equity ratio of 1.90.
| Current Ratio | 1.46 |
| Quick Ratio | 1.37 |
| Debt / Equity | 1.90 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.20 |
Financial Efficiency
Return on equity (ROE) is -46.67% and return on invested capital (ROIC) is -10.46%.
| Return on Equity (ROE) | -46.67% |
| Return on Assets (ROA) | -8.77% |
| Return on Invested Capital (ROIC) | -10.46% |
| Return on Capital Employed (ROCE) | -34.59% |
| Revenue Per Employee | $406,734 |
| Profits Per Employee | -$113,325 |
| Employee Count | 1,488 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 3.72 |
Taxes
In the past 12 months, NovoCure has paid $37.47 million in taxes.
| Income Tax | 37.47M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +28.83% in the last 52 weeks. The beta is 0.63, so NovoCure's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | +28.83% |
| 50-Day Moving Average | 21.79 |
| 200-Day Moving Average | 20.56 |
| Relative Strength Index (RSI) | 39.74 |
| Average Volume (20 Days) | 858,468 |
Short Selling Information
The latest short interest is 5.40 million, so 4.91% of the outstanding shares have been sold short.
| Short Interest | 5.40M |
| Short Previous Month | 5.22M |
| Short % of Shares Out | 4.91% |
| Short % of Float | 5.40% |
| Short Ratio (days to cover) | 4.80 |
Income Statement
In the last 12 months, NovoCure had revenue of $605.22 million and -$168.63 million in losses. Loss per share was -$1.56.
| Revenue | 605.22M |
| Gross Profit | 469.05M |
| Operating Income | -167.54M |
| Pretax Income | -141.13M |
| Net Income | -168.63M |
| EBITDA | -157.67M |
| EBIT | -167.54M |
| Loss Per Share | -$1.56 |
Full Income StatementBalance Sheet
The company has $959.87 million in cash and $683.34 million in debt, giving a net cash position of $276.53 million or $2.52 per share.
| Cash & Cash Equivalents | 959.87M |
| Total Debt | 683.34M |
| Net Cash | 276.53M |
| Net Cash Per Share | $2.52 |
| Equity (Book Value) | 360.18M |
| Book Value Per Share | 3.32 |
| Working Capital | 350.20M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$26.37 million and capital expenditures -$42.86 million, giving a free cash flow of -$69.22 million.
| Operating Cash Flow | -26.37M |
| Capital Expenditures | -42.86M |
| Free Cash Flow | -69.22M |
| FCF Per Share | -$0.63 |
Full Cash Flow StatementMargins
Gross margin is 77.50%, with operating and profit margins of -27.68% and -27.86%.
| Gross Margin | 77.50% |
| Operating Margin | -27.68% |
| Pretax Margin | -21.67% |
| Profit Margin | -27.86% |
| EBITDA Margin | -26.05% |
| EBIT Margin | -27.68% |
| FCF Margin | n/a |
Dividends & Yields
NovoCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.36% |
| Shareholder Yield | -1.36% |
| Earnings Yield | -8.13% |
| FCF Yield | -3.34% |
Dividend DetailsAnalyst Forecast
The average price target for NovoCure is $37.50, which is 107.41% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $37.50 |
| Price Target Difference | 107.41% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 20.10% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NovoCure has an Altman Z-Score of 0.4 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.4 |
| Piotroski F-Score | 4 |